Back to results
US 2022/0105173 A1Published application
Vaccination using herpesvirus genomes in nucleic acid form
AssigneeThe Regents of the University of California
InventorsDennis Hartigan-O'Connor, Peter Barry, Jesse Deere, Joseph Dutra
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for inducing immune responses in subjects using HV-based vectors that can be grown in single celled organisms and administered in their nucleic acid form.
Claims63
A recombinant polynucleotide comprising:
- (a) a herpesvirus (HV) genome or a substantial portion thereof;
- (b) a sequence comprising an origin of replication that functions in a single-celled organism;
- (c) one or more terminase complex recognition loci (TCRL) comprising a recombinantly introduced polynucleotide sequence that can direct cleavage by an HV terminase complex;
- wherein
- the HV genome or portion thereof is separated from the sequence comprising an origin of replication by a TCRL;
- wherein
- the HV genome or portion thereof abuts a TCRL at at least one extremity;
- and wherein
- the sequence comprising the origin of replication abuts a TCRL at at least one extremity.
6 more elements
A recombinant polynucleotide comprising a herpesvirus (HV) genome or a substantial portion thereof, wherein
- the HV genome or substantial portion thereof comprises a nucleic acid sequence encoding a heterologous antigen, and wherein
- one or more TCRLs are introduced between or within one or more genes within the HV genome or substantial portion thereof, such that HV terminase action on the one or more introduced TCRLs leads to the inactivation or deletion of the one or more genes within the HV genome or portion thereof.
Dependencies are inferred from the claim text.